Puma Biotech swings to Q2 profit of $0.21/sh; NERLYNX revenue up 5%

PUMA BIOTECHNOLOGY, INC.

2022-Q2 EPS reported $0.14 revenue$105,254,000

GAAP net income $9.4M ($0.21 per share) vs net loss of $5.1M ($0.13 loss) in Q2 2021.
Total revenue $59.5M ($51.3M product, $8.2M royalties) vs $53.4M in Q2 2021.
Operating expenses fell sharply: SG&A $20.6M (down 48%), R&D $11.9M (down 36%).
Cash and securities $60.8M at June 30, down from $82.1M at Dec 31, 2021.
Management guides for FDA meetings on registration pathways for neratinib in H2 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.